J. Alexandre

1.2k total citations
45 papers, 755 citations indexed

About

J. Alexandre is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, J. Alexandre has authored 45 papers receiving a total of 755 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in J. Alexandre's work include Cancer Treatment and Pharmacology (11 papers), Ovarian cancer diagnosis and treatment (9 papers) and Renal cell carcinoma treatment (5 papers). J. Alexandre is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Ovarian cancer diagnosis and treatment (9 papers) and Renal cell carcinoma treatment (5 papers). J. Alexandre collaborates with scholars based in France, United States and Germany. J. Alexandre's co-authors include François Goldwasser, Jean‐Marc Tréluyer, J.L. Misset, A. Tran, J.M. Gornet, Bruno Falissard, Gérard Pons, Olivier Mir, François Goldwasser and J. Durand and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J. Alexandre

41 papers receiving 738 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Alexandre France	15	370	205	170	149	134	45	755
K. Buser Switzerland	12	409 1.1×	111 0.5×	130 0.8×	323 2.2×	278 2.1×	17	875
M Soukop United Kingdom	19	575 1.6×	169 0.8×	236 1.4×	215 1.4×	188 1.4×	48	1.1k
Davide Lombardi Italy	17	609 1.6×	308 1.5×	210 1.2×	96 0.6×	70 0.5×	57	1.0k
D A Noe United States	16	650 1.8×	191 0.9×	455 2.7×	123 0.8×	78 0.6×	22	1.2k
Nina Keldsen Denmark	13	373 1.0×	135 0.7×	99 0.6×	113 0.8×	55 0.4×	31	602
Ken Shimada Japan	22	694 1.9×	437 2.1×	260 1.5×	312 2.1×	56 0.4×	104	1.3k
Donglin Sun China	19	266 0.7×	250 1.2×	283 1.7×	430 2.9×	33 0.2×	54	1.0k
Douglas Adamson United Kingdom	16	276 0.7×	123 0.6×	160 0.9×	190 1.3×	170 1.3×	40	853
Gianmaria Miolo Italy	17	399 1.1×	166 0.8×	423 2.5×	111 0.7×	34 0.3×	86	996
Seiichi Hayato Japan	13	259 0.7×	212 1.0×	125 0.7×	83 0.6×	26 0.2×	26	855

Countries citing papers authored by J. Alexandre

Since Specialization

Citations

This map shows the geographic impact of J. Alexandre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Alexandre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Alexandre more than expected).

Fields of papers citing papers by J. Alexandre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Alexandre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Alexandre. The network helps show where J. Alexandre may publish in the future.

Co-authorship network of co-authors of J. Alexandre

This figure shows the co-authorship network connecting the top 25 collaborators of J. Alexandre. A scholar is included among the top collaborators of J. Alexandre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Alexandre. J. Alexandre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grimm, Christian, Roman Kocián, Hannelore Denys, et al.. (2024). 712MO Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR). Annals of Oncology. 35. S546–S546. 2 indexed citations

Jouinot, Anne, Camille Tlemsani, Audrey Thomas‐Schoemann, et al.. (2021). 1549P Pazopanib exposure in advanced soft tissue and bone sarcoma: A pharmacokinetic/pharmacodynamic analysis. Annals of Oncology. 32. S1125–S1125. 1 indexed citations

Huillard, Olivier, Évanguelos Xylinas, Pascaline Boudou‐Rouquette, et al.. (2019). Évaluation pluridisciplinaire préopératoire systématique en chirurgie cancérologique urologique gériatrique : faisabilité et résultats. Progrès en Urologie. 29(6). 318–325.

Bretagne, Marie, Anne Jouinot, Jean-Philippe Durand, et al.. (2017). Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity. Cancer Chemotherapy and Pharmacology. 80(1). 45–53. 19 indexed citations

Poveda, Andrés, Isabelle Ray‐Coquard, J. Alexandre, et al.. (2017). Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Annals of Oncology. 28(6). 1280–1287. 40 indexed citations

Elaidi, Réza, Yann Vano, Nicolas Aide, et al.. (2016). Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases. Annals of Oncology. 27. vi295–vi295. 36 indexed citations

Ferron, Gwénaël, Gaëtan De Rauglaudre, Isabelle Laure Ray-Coquard, et al.. (2016). The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome. Annals of Oncology. 27. vi297–vi297. 3 indexed citations

Noé, Gaëlle, Olivier Huillard, Lisa Golmard, et al.. (2016). Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. European Journal of Cancer. 72. 54–61. 49 indexed citations

Velter, C., et al.. (2016). Transfusion de globules rouges en situation oncologique palliative. Transfusion Clinique et Biologique. 23(3). 151–156. 1 indexed citations

10.

Lavaud, Pernelle, Benoı̂t Rousseau, Jennifer Arrondeau, et al.. (2016). Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis. Breast Cancer Research and Treatment. 157(1). 191–192. 12 indexed citations

11.

Alexandre, J., Chris Brown, David Coeffic, et al.. (2012). CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. British Journal of Cancer. 106(4). 633–637. 27 indexed citations

12.

Lortholary, Alain, R. Largillier, B. Weber, et al.. (2011). Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO). Annals of Oncology. 23(2). 346–352. 71 indexed citations

13.

Coriat, Romain, Wioleta Marut, Mahaut Leconte, et al.. (2011). The organotelluride catalyst LAB027 prevents colon cancer growth in the mice. Cell Death and Disease. 2(8). e191–e191. 19 indexed citations

14.

Mir, Olivier, J. Alexandre, A. Tran, et al.. (2009). Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Annals of Oncology. 20(4). 736–740. 70 indexed citations

15.

Trédaniel, Jean, Catherine Becht, Hubert de Crémoux, et al.. (2008). An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients. Lung Cancer. 63(2). 259–263. 4 indexed citations

16.

Puisset, Florent, J. Alexandre, Jean‐Marc Tréluyer, et al.. (2007). Clinical pharmacodynamic factors in docetaxel toxicity. British Journal of Cancer. 97(3). 290–296. 29 indexed citations

17.

Alexandre, J., Elisabeth Rey, V. Girre, et al.. (2006). Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Annals of Oncology. 18(1). 168–172. 51 indexed citations

18.

Alexandre, J., et al.. (2002). Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Annals of Oncology. 14(1). 36–41. 99 indexed citations

19.

Alexandre, J., Karim Fizazi, C Mahé, et al.. (2001). Stage I non-seminomatous germ-cell tumours of the testis. European Journal of Cancer. 37(5). 576–582. 48 indexed citations

20.

Soulié, P, Hassan Errihani, Anne Bessard, et al.. (1997). 6-day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. Journal of Cancer Research and Clinical Oncology. 123(4). 227–231. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact